Filter Results
:
(307)
Show Results For
-
All HBS Web
(307)
- People (1)
- News (126)
- Research (143)
- Multimedia (13)
- Faculty Publications (85)
Show Results For
-
All HBS Web
(307)
- People (1)
- News (126)
- Research (143)
- Multimedia (13)
- Faculty Publications (85)
- Web
Curriculum - MBA
to Achieve Durable Anti-Microbial Host Defense This course will focus on broadly neutralizing and protective anti-viral antibody responses and how critical epitope selection on viral glycoproteins can help to achieve long-term immunity, exploring principles that can be...
View Details
- Web
Capstone - MBA
intermediary. The role of RNA has recently been more widely appreciated, and millions are the recipients of a RNA vaccine from Moderna or Pfizer/BioNTech for Covid-19. This project described the potential for circular RNA therapeutics,...
View Details
- Web
Faculty & Advisors - MBA
in the Vaccine Division. Geoff has been consistently ranked as one of Wall Street’s most influential biotechnology analysts. Evan Rachlin MBA ‘10, Harvard University; MD ‘10, Harvard University; AB, Biochemistry and Japanese, Harvard...
View Details
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and...
View Details
Keywords:
Novartis;
GlaxoSmithKline;
Asset Swap;
Acquisitions;
Divestiture;
Strategy Alignment;
Pharmaceuticals;
Strategy;
Business Strategy;
Corporate Strategy;
Diversification;
Consolidation;
Mergers and Acquisitions;
Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- Web
Visit - MBA
to Know the Area Read about the top attractions in Boston. Keep HBS Healthy We encourage all visitors and guests coming to campus to be up to date on their vaccinations and boosters, and we ask that you do not come to campus if you are...
View Details
- February 2021 (Revised May 2021)
- Case
SafeGraph: Selling Data as a Service
By: Ramana Nanda, Abhishek Nagaraj and Allison Ciechanover
Set in January 2021, the CEO of SafeGraph, a four-year-old startup that sold Data as a Service, looked to the future. His aim was to become the most trusted source for data about a physical place. The company provided points of interest (POI) and foot traffic data on...
View Details
Keywords:
Data As A Service;
Monetization;
Pricing;
Business Startups;
Analytics and Data Science;
Consumer Behavior;
Analysis;
Business Model;
Health Pandemics;
Information Industry;
United States
Nanda, Ramana, Abhishek Nagaraj, and Allison Ciechanover. "SafeGraph: Selling Data as a Service." Harvard Business School Case 821-082, February 2021. (Revised May 2021.)
- June 2021
- Article
From Predictions to Prescriptions: A Data-driven Response to COVID-19
By: Dimitris Bertsimas, Léonard Boussioux, Ryan Cory-Wright, Arthur Delarue, Vassilis Digalakis Jr, Alexander Jacquillat, Driss Lahlou Kitane, Galit Lukin, Michael Lingzhi Li, Luca Mingardi, Omid Nohadani, Agni Orfanoudaki, Theodore Papalexopoulos, Ivan Paskov, Jean Pauphilet, Omar Skali Lami, Bartolomeo Stellato, Hamza Tazi Bouardi, Kimberly Villalobos Carballo, Holly Wiberg and Cynthia Zeng
The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at...
View Details
Keywords:
COVID-19;
Health Pandemics;
AI and Machine Learning;
Forecasting and Prediction;
Analytics and Data Science
Bertsimas, Dimitris, Léonard Boussioux, Ryan Cory-Wright, Arthur Delarue, Vassilis Digalakis Jr, Alexander Jacquillat, Driss Lahlou Kitane, Galit Lukin, Michael Lingzhi Li, Luca Mingardi, Omid Nohadani, Agni Orfanoudaki, Theodore Papalexopoulos, Ivan Paskov, Jean Pauphilet, Omar Skali Lami, Bartolomeo Stellato, Hamza Tazi Bouardi, Kimberly Villalobos Carballo, Holly Wiberg, and Cynthia Zeng. "From Predictions to Prescriptions: A Data-driven Response to COVID-19." Health Care Management Science 24, no. 2 (June 2021): 253–272.
- September 2022
- Case
Deciding When to Engage on Societal Issues
By: Hubert Joly and Amram Migdal
This case provides brief descriptions of 18 examples of corporate leaders confronting questions of whether and how to engage with societal issues, including social, political, and environmental issues. Social issues include COVID-19; social and racial justice;...
View Details
Keywords:
Political Issues;
Social Justice;
Racial Justice;
Environmental Issues;
Social Issues;
Corporate Social Responsibility and Impact;
Values and Beliefs
Joly, Hubert, and Amram Migdal. "Deciding When to Engage on Societal Issues." Harvard Business School Case 523-045, September 2022.
- January–February 2023
- Article
Forecasting COVID-19 and Analyzing the Effect of Government Interventions
By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas
We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more...
View Details
Keywords:
COVID-19 Pandemic;
Epidemics;
Analytics and Data Science;
Health Pandemics;
AI and Machine Learning;
Forecasting and Prediction
Li, Michael Lingzhi, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis, and Dimitris Bertsimas. "Forecasting COVID-19 and Analyzing the Effect of Government Interventions." Operations Research 71, no. 1 (January–February 2023): 184–201.
- Web
Marketing - Faculty & Research
the time and find comfort. Then, amid growing shortages in commodities, a vaccine arrived, businesses began to re-open, and consumers benefited from federal relief aid. This perfect storm of high demand amid stock shortages generated the...
View Details
- January 2009
- Case
When Supply is of Public Interest: Roche & Tamiflu
The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic...
View Details
Keywords:
Global Strategy;
Health Pandemics;
Distribution;
Logistics;
Production;
Supply Chain Management;
Performance Capacity;
Pharmaceutical Industry
Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
- Web
FAQs - Alumni
www.bostonsbestbabysitters.com Contact (please text): Jennifer Cole 617-455-7171 All childcare providers are fully vaccinated and have worked with Boston Best Babysitters for at least three (3) years. Parents will receive a full profile...
View Details
- 17 Aug 2020
- Research & Ideas
What the Stockdale Paradox Tells Us About Crisis Leadership
herd immunity. But to review the brutal facts, none of these developments are likely in the foreseeable short term. The possibility remains that there may never be a fully effective vaccine or cure; this virus may be something that we...
View Details
Keywords:
by Boris Groysberg and Robin Abrahams
- Portrait Project
Albert Chiu
COVID-19. As a chemical engineer, I designed the process to manufacture Moderna and Pfizer’s mRNA COVID-19 vaccines. I developed new technologies to improve how vaccines are manufactured and shortened production time in half for Operation...
View Details
- Web
HBS Health Care Initiative - Blog: Health Supplement
the Next Pandemic Vaccine to Your Doorstep with MIMIX Michael Schrader Author Alumni tag Biotech/pharma Clinical Trials Health Care Entrepreneurship Health Care Innovation Health Care at HBS As an HBS student in Professor Vicki Sato’s...
View Details
- 13 Jul 2020
- Research & Ideas
Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk
As chairman and CEO of the leading vaccine producer in the world, pharmaceutical giant Merck & Co., Ken Frazier has one of the highest-profile positions in global business. But Frazier, who is leading one of the firms on a charge to...
View Details
- 29 Jul 2021
- Blog Post
Exploring the Intersection of Business & Health Care: Summer Fellow Derek Soled (MD/MBA 2022)
Office. Specifically, I am working on the COVID-19 Vaccine Confidence and Equity project. Many New York City residents are either hesitant to receive the vaccine or lack access to healthcare facilities to...
View Details
- 08 Mar 2021
- In Practice
COVID Killed the Traditional Workplace. What Should Companies Do Now?
A year ago, COVID-19 forced many companies to send employees home—often with a laptop and a prayer. Now, with COVID cases subsiding and vaccinations rising, the prospect of returning to old office routines appears more possible. But will employees want to flock back to...
View Details
Keywords:
by Dina Gerdeman
- 24 Oct 2023
- Research & Ideas
When Tech Platforms Identify Black-Owned Businesses, White Customers Buy
Vaccinated When Design Enables Discrimination: Learning from Anti-Asian Bias on Airbnb Steer Clear of the Blind Spots That Derail Experiments Feedback or ideas to share? Email the Working Knowledge team at hbswk@hbs.edu. Image:...
View Details
- 02 Apr 2020
- What Do You Think?
What Are Lessons for Leaders from This Black Swan Crisis?
communicable virus pandemics are generally predictable since they seem to occur every decade or so, the specific nature of the COVID-19 virus—and therefore the ability to prepare a vaccine for it—could not. True advocates of Black Swan...
View Details
Keywords:
by James Heskett